drughunter.com
11 minute read
Jun. 12, 2024

Pfizer’s CDK4-Selective Inhibitor Overcomes CDK4/6 DLT for Superior Target Coverage and Efficacy

PF-07220060

oral selective CDK4 inhibitor Ph. III for advanced or metastatic HR+/HER2- breast cancer CADD-informed focused screen AACR San Diego 2024, “New Drugs on the Horizon” presentation Pfizer, San Diego, CA

Author:  
Reviewer:  
Editor:  
Loading...

twitterlinkedinemail

Other molecules you may be interested in